Project: Blocking the S1P Pathway for Chronic Kidney Disease Therapeutics
- Company: S1P Therapeutics Inc (Blacksburg, VA)
- University collaborators: Virginia Tech and University of Virginia
- Funding amount: $500,000
S1P Therapeutics Inc is excited that our groundbreaking research in developing drugs for the treatment of kidney and autoimmune diseases has been awarded a prestigious Virginia Catalyst grant. This recognition is a testament to the dedication of our exceptional team, who have tirelessly pursued innovations that have the potential to improve the lives of Chronic Kidney Disease (CKD) patients. Blocking the S1P (sphingosine 1-phosphate) pathway is a novel therapeutic target for CKD. In collaboration with Prof. Webster Santos at Virginia Tech and Prof. Kevin Lynch at the University of Virginia, S1P Therapeutics will use the Catalyst funding to progress our experimental drugs towards the clinic. CKD is a progressive condition that affects over 800 million people worldwide and often progresses to kidney failure. We are uniquely positioned to address this challenge and are committed to making a meaningful impact in the lives of CKD patients.
– Ron Sayco, Chief Executive Officer, S1P Therapeutics Inc